Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Summary: CLL Highlights

2024 ASH Annual Meeting Insights Hub

A. Danilov

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

Year in Review 2024: CLL Highlights

The University of Kansas Cancer Center

M. Hoffmann

ASH 2024 Insights: Ph 3 AMPLIFY - Fixed-Duration Acalabrutinib + Ven…

2024 ASH Annual Meeting Insights Hub

J. Brown

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

CLL in 2024: Evolution of the Role of Novel Targeted Therapies

Louisville Hematology Highlights

C. Coombs

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

Emerging Trends in the Treatment Landscape of CLL

Moffitt Cancer Center

J. Pinilla-Ibarz

ASH 2024 Insights: Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

Approach to Treatment Selection and Personalization in 1L CLL

Dima El-Sharkawi

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Pirtobrutinib in CLL: Current and Potential Utility in the Treatment…

Nicole Lamanna

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients…

2024 ASH Annual Meeting Insights Hub

M. Shadman

Guideline-Based Treatment Approaches in CLL

Farrukh Awan

Current Guideline-Informed Treatment of CLL

Fred Hutchinson Cancer Center

C. Ujjani